Camp4 Therapeutics (CAMP) Net Income (2023 - 2026)
Camp4 Therapeutics (CAMP) posted Net Income of -$12.2 million for Q1 2026, down 26.33% sequentially from -$9.7 million in Q4 2025, and up 10.49% YoY from -$11.1 million in Q1 2025.
Camp4 Therapeutics (CAMP) Net Income (2023 - 2026) Analysis & Trends
Camp4 Therapeutics has reported Net Income for 4 years, with the latest figure at -$12.2 million in Q1 2026.
- Quarterly Net Income rose 10.49% year-over-year to -$12.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$56.1 million (up 8.65% YoY) and the FY2025 annual result came in at -$126.5 million, down 8.44% from the prior year.
- Net Income eased to -$12.2 million in Q1 2026 per CAMP's latest filing, from -$9.7 million in the prior quarter.
- Over five years, Net Income peaked at -$9.7 million in Q4 2025 and troughed at -$23.8 million in Q3 2024.
- A 4-year average of -$14.2 million and a median of -$13.1 million in 2024 frame the typical range for Net Income.
- The sharpest annual moves came in 2024 and 2025: Net Income slumped 91.67% in 2024, then surged 40.68% in 2025.
- Over 4 years, Net Income stood at -$13.0 million in 2023, then climbed by 15.83% to -$10.9 million in 2024, then rose by 11.55% to -$9.7 million in 2025, then fell by 26.33% to -$12.2 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$12.2 million, -$9.7 million, and -$14.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Camp4 Therapeutics | 282.48 Mn | 282.48 Mn | - | -15.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.05 Mn |
| Mar 31, 2026 | -12.22 Mn |
| Dec 31, 2025 | -9.67 Mn |
| Sep 30, 2025 | -14.10 Mn |
| Jun 30, 2025 | -20.13 Mn |
| Mar 31, 2025 | -13.65 Mn |
| Dec 31, 2024 | -10.93 Mn |
| Sep 30, 2024 | -23.78 Mn |
| Jun 30, 2024 | -13.08 Mn |
| Mar 31, 2024 | -13.58 Mn |
| Dec 31, 2023 | -12.99 Mn |
| Sep 30, 2023 | -12.40 Mn |